Centanafadine
Centanafadine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is being investigated for the treatment of attention deficit hyperactivity disorder (ADHD). It is known for its unique pharmacological profile, which involves the inhibition of the reuptake of three key neurotransmitters: serotonin, norepinephrine, and dopamine.
Pharmacology[edit]
Centanafadine works by inhibiting the reuptake of serotonin, norepinephrine, and dopamine, which increases the levels of these neurotransmitters in the synaptic cleft and enhances neurotransmission. This mechanism is believed to contribute to its therapeutic effects in managing symptoms of ADHD.
Mechanism of Action[edit]
The drug's mechanism of action involves binding to the transporters responsible for the reuptake of serotonin, norepinephrine, and dopamine. By inhibiting these transporters, centanafadine increases the concentration of these neurotransmitters in the synaptic cleft, thereby enhancing their activity in the brain.
Clinical Trials[edit]
Centanafadine has undergone several clinical trials to evaluate its efficacy and safety in treating ADHD. These trials have shown promising results, indicating that centanafadine may be an effective treatment option for individuals with ADHD.
Side Effects[edit]
As with any medication, centanafadine may cause side effects. Common side effects observed in clinical trials include insomnia, dry mouth, headache, and nausea. It is important for patients to discuss potential side effects with their healthcare provider.
Comparison with Other ADHD Medications[edit]
Centanafadine is distinct from other ADHD medications such as methylphenidate and amphetamine-based treatments due to its triple reuptake inhibition mechanism. This unique profile may offer advantages in terms of efficacy and side effect profile.
Future Directions[edit]
Ongoing research is focused on further understanding the long-term effects and potential benefits of centanafadine in treating ADHD. Additional studies are needed to fully establish its place in the therapeutic landscape for ADHD.
See Also[edit]
- Attention deficit hyperactivity disorder
- Serotonin-norepinephrine-dopamine reuptake inhibitor
- Serotonin
- Norepinephrine
- Dopamine
- Methylphenidate
- Amphetamine
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
